Very much agree with your view. That means the program is going to be swift. Starting from the first-patient first-dose, to the completion of the phase 2 trial, plus a peer review that follows, the FDA assessments and approval and to tick off to start phase 3. All within the next 22 months or so.
Coupled with IRX616A for the same program, as @JasonBourne007 had mentioned, we are going to see a gangbusters amount of news flow soon.
Add to My Watchlist
What is My Watchlist?
